These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2284102)

  • 1. A potential transcriptional activation element in the p53 protein.
    O'Rourke RW; Miller CW; Kato GJ; Simon KJ; Chen DL; Dang CV; Koeffler HP
    Oncogene; 1990 Dec; 5(12):1829-32. PubMed ID: 2284102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
    Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
    Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
    Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
    Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SV40 T antigen abrogates p53-mediated transcriptional activity.
    Jiang D; Srinivasan A; Lozano G; Robbins PD
    Oncogene; 1993 Oct; 8(10):2805-12. PubMed ID: 8378089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1.
    Huang SM; Schönthal AH; Stallcup MR
    Oncogene; 2001 Apr; 20(17):2134-43. PubMed ID: 11360197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
    Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
    Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional interplay between p53 and E2F through co-activator p300.
    Lee CW; Sørensen TS; Shikama N; La Thangue NB
    Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-mediated transcription induces resistance of DNA to UV inactivation.
    Huang J; Logsdon N; Schmieg FI; Simmons DT
    Oncogene; 1998 Jul; 17(4):401-11. PubMed ID: 9696032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
    Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
    Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. deltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes.
    King KE; Ponnamperuma RM; Yamashita T; Tokino T; Lee LA; Young MF; Weinberg WC
    Oncogene; 2003 Jun; 22(23):3635-44. PubMed ID: 12789272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site.
    Suzuki T; Uchida-Toita M; Yoshida M
    Oncogene; 1999 Jul; 18(28):4137-43. PubMed ID: 10435595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the human stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products.
    Seth A; Giunta S; Franceschil C; Kola I; Venanzoni MC
    Cell Death Differ; 1999 Sep; 6(9):902-7. PubMed ID: 10510472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K; Li B; Bartel P; Fields S
    Oncogene; 1993 Jun; 8(6):1693-6. PubMed ID: 8502489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a p53-dependent negative response element in the bcl-2 gene.
    Miyashita T; Harigai M; Hanada M; Reed JC
    Cancer Res; 1994 Jun; 54(12):3131-5. PubMed ID: 8205530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
    Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
    Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
    Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
    Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 transactivation through various p53-responsive elements.
    Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
    Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 amino acids 339-346 represent the minimal p53 repression domain.
    Hong TM; Chen JJ; Peck K; Yang PC; Wu CW
    J Biol Chem; 2001 Jan; 276(2):1510-5. PubMed ID: 11007800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.